Oncolytics Biotech Inc. plans to wind down its GOBLET gastrointestinal study and reallocate resources toward registration-focused and registration-enabling programs for pelareorep in squamous cell anal cancer (SCAC) and metastatic colorectal cancer $(CRC)$. The company expects to meet with the U.S. Food and Drug Administration in mid-April to align on the design of a U.S.-based single-arm SCAC registrational study, which it believes could enroll well under 100 patients. Oncolytics will stop further enrollment in the GOBLET Cohort 5 metastatic pancreatic ductal adenocarcinoma arms at about 20 patients per arm, continue following enrolled patients, and report results when the data mature.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240900PRIMZONEFULLFEED9659818) on February 24, 2026, and is solely responsible for the information contained therein.